首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy
【24h】

Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy

机译:在6次化疗后,通过免疫组织化学在生发中心和发芽后中心组的预后亚分组

获取原文
获取外文期刊封面目录资料

摘要

Introduction: Diffuse large B-cell lymphomas (DLBCL) can be divided into germinal centre (GC-DLBCL) and post germinal centre (post GC-DLBCL) groups by applying immunohistochemical antibodies. As these subgroups respond differently to chemotherapy, it is possible at diagnosis to select a poor prognostic subgroup for aggressive treatment. Objective: To determine the frequencies of GC-DLBCL and post GC-DLBCL in patients by immunohistochemistry (IHC) and the clinical response after six cycles of chemotherapy. Subjects and Methods: In this descriptive study conducted in AFIP and CMH, Rawalpindi and NORI, Islamabad, from September 2010 to September 2011, a total of 75 pretreatment cases of DLBCL diagnosed during the study period were included. Cases were segregated in to GC-DLBCL and post GC-DLBCL groups according to results of immunohistochemistry markers CD10, BCL6 and MUM1. Immediate clinical response was assessed after 6 cycles of chemotherapy. Response was divided into complete response, partial response, stable disease or relapse or progression. Results: The mean age was . Males were 53 (70.7%). Forty (53.3%) cases comprised the GC-DLBCL group; 25(62.5%) of them showed a complete response. Most patients of the post GC-DLBCL 19(54%) showed relapse/progression. Results of immediate clinical response in both prognostic subgroups were significant (p0.05). Results regarding positivity with immunohistochemical antibodies CD10 (p 0.011), BCL6 (p 0.013) and MUM1 (p 0.000) regarding immediate clinical response were also significant. Conclusion: GC-DLBCL group shows better response to CHOP chemotherapy regimen. Immunohistochemistry should be used to further classify DLBCL as this can enable us to select aggressive group for aggressive treatment. This manuscript is important because the study is the first to becarried out exclusively in Pakistan or our part of the world.
机译:简介:通过施加免疫组织化学抗体,弥漫性大B细胞淋巴瘤(DLBCL)可分为生发中心(GC-DLBCL)和发芽后中心(后GC-DLBCL)组。随着这些亚组对化疗的反应不同,诊断有可能选择较差的预后亚组以进行激进治疗。目的:通过免疫组织化学(IHC)确定G​​C-DLBCL和后GC-DLBCL后的频率和六周期化疗后的临床反应。主题和方法:在2010年9月至2011年9月的AFIP和CMH,Rapalpindi和Nori,伊斯兰堡进行的这种描述性研究中,包括在研究期间诊断的75例DLBCL预处理病例。将病例分离在GC-DLBCL和后GC-DLBCL基团根据免疫组织化学标记CD10,BCL6和MUM1的结果。在6个循环化疗后评估即时临床反应。响应分为完全反应,部分响应,稳定疾病或复发或进展。结果:平均年龄是。男性为53(70.7%)。四十(53.3%)案件包括GC-DLBCL组;其中25(62.5%)显示了完整的回应。大多数患者GC-DLBCL 19(54%)显示复发/进展。预后亚组在两种预后临床反应的结果是显着的(P <0.05)。关于免疫组织化学抗体的阳性CD10(P 0.011),BCL6(P 0.013)和均值的结果也显着。结论:GC-DLBCL组表现出对切碎化疗方案的更好反应。免疫组化应用于进一步分类DLBCL,因为这使我们能够选择积极的群体进行积极处理。这份手稿很重要,因为这项研究是第一个在巴基斯坦或我们的世界各地被完全被淘汰的人。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号